Страна: Канада
Язык: английский
Источник: Health Canada
BETAMETHASONE (BETAMETHASONE DIPROPIONATE); CLOTRIMAZOLE
TARO PHARMACEUTICALS INC
D01AC20
IMIDAZOLES/TRIAZOLES IN COMBINATION WITH CORTICOSTEROIDS
0.05%; 1%
CREAM
BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%; CLOTRIMAZOLE 1%
TOPICAL
15G/50G
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0216399001; AHFS:
APPROVED
2020-02-19
_Page 1 of 17_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TARO-CLOTRIMAZOLE/BETAMETHASONE DIPROPIONATE Clotrimazole and Betamethasone Dipropionate Cream, USP 1% w/w clotrimazole / 0.05% w/w betamethasone (as betamethasone dipropionate) Topical Antifungal and Corticosteroid Agent Taro Pharmaceuticals Inc. Date of Revision: 130 East Drive March 29, 2021 Brampton, ON L6T 1C1 Submission Control Number: 246369 _Page 2 of 17_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 1 INDICATIONS ..................................................................................................................3 1.1 Pediatrics....................................................................................................................3 1.2 Geriatrics ....................................................................................................................3 2 CONTRAINDICATIONS .................................................................................................3 3 DOSAGE AND ADMINISTRATION .............................................................................3 3.1 Dosing Considerations ...............................................................................................3 3.2 Recommended Dose and Dosage Adjustment ...........................................................3 3.3 Administration ...........................................................................................................4 4 MISSED DOSE ..................................................................................................................4 5 OVERDOSAGE .................................................................................................................4 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................5 7 WARNINGS AND PRECAUTIONS ...............................................................................5 7.1 Special Populations ................................................... Прочитать полный документ